SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/31/14 MusclePharm Corp 10-Q/A 6/30/14 92:9M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 10-Q/A Amendment to Quarterly Report HTML 356K 2: EX-31.1 Certification -- §302 - SOA'02 HTML 31K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 31K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 26K 5: EX-32.2 Certification -- §906 - SOA'02 HTML 26K 62: R1 Document And Entity Information HTML 49K 49: R2 Consolidated Balance Sheets HTML 137K 60: R3 Consolidated Balance Sheets [Parenthetical] HTML 49K 64: R4 Consolidated Statements of Operations HTML 111K 84: R5 Consolidated Statements of Cash Flows HTML 157K 51: R6 Nature of Operations and Basis of Presentation HTML 32K 59: R7 Summary of Significant Accounting Policies HTML 70K 44: R8 Composition of Certain Financial Statement HTML 154K Captions 34: R9 Concentrations HTML 68K 85: R10 Financial Instruments HTML 46K 66: R11 Debt HTML 54K 65: R12 Derivative Liabilities HTML 35K 71: R13 Restricted Stock Units HTML 36K 72: R14 Stockholders' Equity HTML 114K 69: R15 Commitments, Contingencies and Other Matters HTML 71K 73: R16 Defined Contribution Plan HTML 30K 61: R17 Related Party Transactions HTML 35K 63: R18 Endorsement Agreement HTML 29K 68: R19 Biozone Acquisition HTML 122K 92: R20 Intangible Assets HTML 66K 80: R21 Restatement of June 30, 2014 Unaudited HTML 118K Consolidated Financial Statements 55: R22 Subsequent Events HTML 31K 67: R23 Summary of Significant Accounting Policies HTML 139K (Policies) 57: R24 Concentrations (Tables) HTML 68K 25: R25 Composition of Certain Financial Statement HTML 164K Captions (Tables) 81: R26 Financial Instruments (Tables) HTML 40K 88: R27 Debt (Tables) HTML 51K 39: R28 Derivative Liabilities (Tables) HTML 32K 38: R29 Stockholders' Equity (Tables) HTML 108K 42: R30 Committments, Contingencies and Other Matters HTML 65K (Tables) 43: R31 Biozone Acquisition (Tables) HTML 116K 45: R32 Intangible Assets (Tables) HTML 67K 19: R33 Restatement of June 30, 2014 Unaudited HTML 113K Consolidated Financial Statements (Tables) 78: R34 Composition of Certain Financial Statement HTML 35K Captions (Details) 53: R35 Composition of Certain Financial Statement HTML 39K Captions (Details 1) 56: R36 Composition of Certain Financial Statement HTML 55K Captions (Details 2) 29: R37 Composition of Certain Financial Statement HTML 33K Captions (Details 3) 91: R38 Composition of Certain Financial Statement HTML 32K Captions (Details 5) 12: R39 Composition of Certain Financial Statement HTML 51K Captions (Details 4) 46: R40 Composition of Certain Financial Statement HTML 47K Captions (Details 6) 83: R41 Composition of Certain Financial Statement HTML 34K Captions (Details 7) 27: R42 Composition of Certain Financial Statement HTML 35K Captions (Details 8) 37: R43 Composition of Certain Financial Statement HTML 28K Captions (Details Textual) 41: R44 Concentrations (Details) HTML 33K 50: R45 Concentrations (Details 1) HTML 33K 18: R46 Concentrations (Details 2) HTML 30K 33: R47 Financial Instruments (Details) HTML 41K 14: R48 Financial Instruments (Details Textual) HTML 26K 82: R49 Debt (Details) HTML 44K 26: R50 Debt (Details 1) HTML 30K 79: R51 Debt (Details 2) HTML 30K 30: R52 Debt (Details Textual) HTML 47K 47: R53 Derivative Liabilities (Details) HTML 34K 13: R54 Derivative Liabilities (Details Textual) HTML 30K 17: R55 Restricted Stock Units (Details Textual) HTML 71K 40: R56 Stockholders' Equity (Details) HTML 55K 21: R57 Stockholders' Equity (Details 1) HTML 30K 86: R58 Stockholders' Equity (Details 2) HTML 48K 52: R59 Stockholders' Equity (Details 3) HTML 53K 70: R60 Stockholders' Equity (Details Textual) HTML 41K 32: R61 Commitments, Contingencies and Other Matters HTML 45K (Details) 35: R62 Commitments, Contingencies and Other Matters HTML 41K (Details 1) 77: R63 Commitments, Contingencies and Other Matters HTML 40K (Details 2) 75: R64 Commitments, Contingencies and Other Matters HTML 53K (Details Textual) 54: R65 Defined Contribution Plan (Details Textual) HTML 29K 76: R66 Related Party Transactions (Details Textual) HTML 51K 31: R67 Endorsement Agreement (Details Textual) HTML 28K 58: R68 Biozone Acquisition (Details) HTML 63K 87: R69 Biozone Acquisition (Details 1) HTML 32K 16: R70 Biozone Acquisition (Details 2) HTML 42K 24: R71 Biozone Acquisition (Details Textual) HTML 36K 48: R72 Intangible Assets (Details) HTML 43K 20: R73 Intangible Assets (Details 1) HTML 41K 90: R74 Intangible Assets (Details Textual) HTML 28K 28: R75 Restatement of June 30, 2014 Unaudited HTML 113K Consolidated Financial Statements (Details) 22: R76 Restatement of June 30, 2014 Unaudited HTML 32K Consolidated Financial Statements (Details Textual) 23: R77 Subsequent Events (Details Textual) HTML 39K 89: XML IDEA XML File -- Filing Summary XML 136K 15: EXCEL IDEA Workbook of Financial Reports XLSX 190K 36: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.52M 6: EX-101.INS XBRL Instance -- mslp-20140630 XML 2.06M 8: EX-101.CAL XBRL Calculations -- mslp-20140630_cal XML 220K 9: EX-101.DEF XBRL Definitions -- mslp-20140630_def XML 1.09M 10: EX-101.LAB XBRL Labels -- mslp-20140630_lab XML 1.27M 11: EX-101.PRE XBRL Presentations -- mslp-20140630_pre XML 1.22M 7: EX-101.SCH XBRL Schema -- mslp-20140630 XSD 230K 74: ZIP XBRL Zipped Folder -- 0001144204-14-064325-xbrl Zip 191K
Exhibit 31.1
CERTIFICATION
I, Brad J. Pyatt, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q/A of MusclePharm Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: October 31, 2014 | By: | /s/ Brad J. Pyatt |
Brad J. Pyatt | ||
Principal Executive Officer |
C:
This ‘10-Q/A’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 10/31/14 | 10-K/A, 8-K | ||
For Period end: | 6/30/14 | 10-Q | ||
List all Filings |